A tryptophan derivative, ITE, enhances liver Cell metabolic functions in vitro

International Journal of Molecular Medicine

Volumn 39, Issue 1, 2017, Pages 101-112

  Zhang, Xiaoqian ^a   Lu, Juan ^a   He, Bin ^b   Tang, Lingling ^a   Liu, Xiaoli ^a   Zhu, Danhua ^a   Cao, Hongcui ^a   Wang, Yingjie ^a   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

2 (1'H indole 3' carbonyl) thiazole 4 carboxylic acid methyl ester; Cytochrome P450; Metabolic functions; Microspheres

Indexed keywords

2 (1'H INDOLE 3' CARBONYL) THIAZOLE 4 CARBOXYLIC ACID METHYL ESTER; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; FLUORESCEIN DIACETATE; PROPIDIUM IODIDE; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; 2-(1'H-INDOLE-3'-CARBONYL)THIAZOLE-4-CARBOXYLIC ACID METHYL ESTER; ALGINIC ACID; CYTOCHROME P450; GLUCURONIC ACID; HEXURONIC ACID; INDOLE DERIVATIVE; MESSENGER RNA; MICROSPHERE; THIAZOLE DERIVATIVE; TRYPTOPHAN;

ARTICLE; C3A CELL LINE; CELL FUNCTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA MICROARRAY; HUH7 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LIVER CELL; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; STAINING; UREA CYCLE; WESTERN BLOTTING; CELL DEATH; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE ONTOLOGY; GENETICS; LIVER; METABOLISM; TUMOR CELL LINE;

ALGINATES; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION; GENE ONTOLOGY; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; INDOLES; LIVER; MICROSPHERES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; THIAZOLES; TRYPTOPHAN;

EID: 85007559032     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2825     Document Type: Article

References (55)

1. Bernal W and Wendon J: Acute liver failure. N Engl J Med 369:2525-2534, 2013.
2. Tostoes RM, Leite SB, Miranda JP, Sousa M, Wang DI, Carrondo MJ and Alves PM: Perfusion of 3D encapsulated hepatocytes - a synergistic effect enhancing long-term functionality in bioreactors. Biotechnol Bioeng 108:41-49, 2011.
3. Carpentier B, Gautier A and Legallais C: Artificial and bioartificial liver devices: present and future. Gut 58:1690-1702, 2009.
4. Yang Y, Li J, Pan X, Zhou P, Yu X, Cao H, Wang Y and Li L: Co-culture with mesenchymal stem cells enhances metabolic functions of liver cells in bioartificial liver system. Biotechnol Bioeng 110:958-968, 2013.
5. Chamuleau RA, Deurholt T and Hoekstra R: Which are the right cells to be used in a bioartificial liver? Metab Brain Dis 20:327-335, 2005.
6. Nakamura T, Tomita Y, Hirai R, Yamaoka K, Kaji K and Ichihara A: Inhibitory effect of transforming growth factor-beta on DNA synthesis of adult rat hepatocytes in primary culture. Biochem Biophys Res Commun 133:1042-1050, 1985.
7. Zanger UM, Turpeinen M, Klein K and Schwab M: Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108, 2008.
8. Gebhardt R, Hengstler JG, Muller D, Glockner R, Buenning P, Laube B, Schmelzer E, Ullrich M, Utesch D, Hewitt N, et al: New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35:145-213, 2003.
9. Gomez-Lechon MJ, Donato MT, Castell JV and Jover R: Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292-312, 2003.
10. Vermeir M, Annaert P, Mamidi RN, Roymans D, Meuldermans W and Mannens G: Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin Drug Metab Toxicol 1:75-90, 2005.
11. Filippi C, Keatch SA, Rangar D, Nelson LJ, Hayes PC and Plevris JN: Improvement of C3A cell metabolism for usage in bioartificial liver support systems. J Hepatol 41:599-605, 2004.
12. Sivertsson L, Ek M, Darnell M, Edebert I, Ingelman-Sundberg M and Neve EP: CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells. Drug Metab Dispos 38:995-1002, 2010.
13. Sussman NL, Gislason GT, Conlin CA and Kelly JH: The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 18:390-396, 1994.
14. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, Gislason GT, Sussman NL and Williams R: Pilot.controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 24:1446-1451, 1996.
15. Hughes RD, Nicolaou N, Langley PG, Ellis AJ, Wendon JA and Williams R: Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. Artif Organs 22:854-858, 1998.
16. Tsay JJ, Tchou-Wong KM, Greenberg AK, Pass H and Rom WN: Aryl hydrocarbon receptor and lung cancer. Anticancer Res 33:1247-1256, 2013.
17. Cheng J, Li W, Kang B, Zhou Y, Song J, Dan S, Yang Y, Zhang X, Li J, Yin S, et al: Tryptophan derivatives regulate the transcription of Oct4 in stem-like cancer cells. Nat Commun 6:7209, 2015.
18. Minsavage GD, Park SK and Gasiewicz TA: The aryl hydrocarbon receptor (AhR) tyrosine 9, a residue that is essential for AhR DNA binding activity, is not a phosphoresidue but augments AhR phosphorylation. J Biol Chem 279:20582-20593, 2004.
19. Hankinson O: The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35:307-340, 1995.
20. Whitlock JP Jr: Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39:103-125, 1999.
21. Song J, Clagett-Dame M, Peterson RE, Hahn ME, Westler WM, Sicinski RR and DeLuca HF: A ligand for the aryl hydrocarbon receptor isolated from lung. Proc Natl Acad Sci USA 99:14694.14699, 2002.
22. Khetani SR and Bhatia SN: Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126, 2008.
23. Isom HC, Secott T, Georgoff I, Woodworth C and Mummaw J: Maintenance of differentiated rat hepatocytes in primary culture. Proc Natl Acad Sci USA 82:3252-3256, 1985.
24. Dich J, Vind C and Grunnet N: Long-term culture of hepatocytes: effect of hormones on enzyme activities and metabolic capacity. Hepatology 8:39-45, 1988.
25. Kubota H and Reid LM: Clonogenic hepatoblasts, common precursors for hepatocytic and biliary lineages, are lacking classical major histocompatibility complex class I antigen. Proc Natl Acad Sci USA 97:12132-12137, 2000.
26. Allen JW, Hassanein T and Bhatia SN: Advances in bioartificial liver devices. Hepatology 34:447-455, 2001.
27. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F and Guguen. Guillouzo C: The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168:66-73, 2007.
28. Nibourg GA, Huisman MT, van der Hoeven TV, van Gulik TM, Chamuleau RA and Hoekstra R: Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application. Liver Transpl 16:1075-1085, 2010.
29. Wang N, Tsuruoka S, Yamamoto H, Enosawa S, Omasa T, Sata N, Matsumura T, Nagai H and Fujimura A: The bioreactor with CYP3A4- and glutamine synthetase-introduced HepG2 cells: treatment of hepatic failure dog with diazepam overdosage. Artif Organs 29:681-684, 2005.
30. Fujii-Kuriyama Y and Mimura J: Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. Biochem Biophys Res Commun 338:311-317, 2005.
31. Rabanel JM, Banquy X, Zouaoui H, Mokhtar M and Hildgen P: Progress technology in microencapsulation methods for cell therapy. Biotechnol Prog 25:946-963, 2009.
32. Jover R, Moya M and Gomez-Lechon MJ: Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. Curr Drug Metab 10:508-519, 2009.
33. Puga A, Ma C and Marlowe JL: The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 77:713-722, 2009.
34. Marie S, Anderson A and Cresteil T: Transplacental induction of cytochromes P-450IA1 and P-450IA2 by polycyclic aromatic carcinogens: TCDD-binding protein level as the rate-limiting step. Carcinogenesis 9:2059-2063, 1988.
35. Tritscher AM, Goldstein JA, Portier CJ, McCoy Z, Clark GC and Lucier GW: Dose-response relationships for chronic exposure to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Cancer Res 52:3436-3442, 1992.
36. Dohr O, Vogel C and Abel J: Different response of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB 231 cells. Arch Biochem Biophys 321:405-412, 1995.
37. Gonzalez FJ, Tukey RH and Nebert DW: Structural gene products of the Ah locus. Transcriptional regulation of cytochrome P1-450 and P3-450 mRNA levels by 3-methylcholanthrene. Mol Pharmacol 26:117-121, 1984.
38. Goasduff T, Menez JF, Dreano Y and Berthou F: CYP1A2 and 2E1 expression in rat liver treated with combined inducers (3-methylcholanthrene and ethanol). Biochem Biophys Res Commun 211:497-503, 1995.
39. Mimura J and Fujii-Kuriyama Y: Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 1619:263-268, 2003.
40. Kinasiewicz A, Gautier A, Lewinska D, Bukowski J, Legallais C and Weryński A: Culture of C3A cells in alginate beads for fluidized bed bioartificial liver. Transplant Proc 39:2911.2913, 2007.
41. David B, Dufresne M, Nagel MD and Legallais C: In vitro assessment of encapsulated C3A hepatocytes functions in a fluidized bed bioreactor. Biotechnol Prog 20:1204-1212, 2004.
42. Glicklis R, Shapiro L, Agbaria R, Merchuk JC and Cohen S: Hepatocyte behavior within three-dimensional porous alginate scaffolds. Biotechnol Bioeng 67:344-353, 2000.
43. Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y and Puga A: The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res 70:212-220, 2010.
44. Schnekenburger M, Peng L and Puga A: HDAC1 bound to the Cyp1a1 promoter blocks histone acetylation associated with Ah receptor-mediated trans-activation. Biochim Biophys Acta 1769:569-578, 2007.
45. Thasler WE, Dayoub R, Muhlbauer M, Hellerbrand C, Singer T, Grabe A, Jauch KW, Schlitt HJ and Weiss TS: Repression of cytochrome P450 activity in human hepatocytes in vitro by a novel hepatotrophic factor, augmenter of liver regeneration. J Pharmacol Exp Ther 316:822-829, 2006.
46. Vondracek J, Machala M, Bryja V, Chramostova K, Krcmar P, Dietrich C, Hampl A and Kozubik A: Aryl hydrocarbon receptor.activating polychlorinated biphenyls and their hydroxylated metabolites induce cell proliferation in contact-inhibited rat liver epithelial cells. Toxicol Sci 83:53-63, 2005.
47. Curcio E, Salerno S, Barbieri G, De Bartolo L, Drioli E and Bader A: Mass transfer and metabolic reactions in hepatocyte spheroids cultured in rotating wall gas-permeable membrane system. Biomaterials 28:5487-5497, 2007.
48. Beningo KA, Dembo M and Wang YL: Responses of fibroblasts to anchorage of dorsal extracellular matrix receptors. Proc Natl Acad Sci USA 101:18024-18029, 2004.
49. Zhang X, Wang W, Yu W, Xie Y, Zhang X, Zhang Y and Ma X: Development of an in vitro multicellular tumor spheroid model using microencapsulation and its application in anticancer drug screening and testing. Biotechnol Prog 21:1289-1296, 2005.
50. Orive G, Tam SK, Pedraz JL and Halle JP: Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy. Biomaterials 27:3691-3700, 2006.
51. Neubauer MP, Poehlmann M and Fery A: Microcapsule mechanics: from stability to function. Adv Colloid Interface Sci 207:65-80, 2014.
52. Lv G, Zhao L, Zhang A, Du W, Chen Y, Yu C, Pan X, Zhang Y, Song T, Xu J, et al: Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs. Biotechnol Bioeng 108:2229-2236, 2011.
53. Gautier A, Carpentier B, Dufresne M, Vu Dinh Q, Paullier P and Legallais C: Impact of alginate type and bead diameter on mass transfers and the metabolic activities of encapsulated C3A cells in bioartificial liver applications. Eur Cell Mater 21:94-106, 2011.
54. Hoshikawa A, Nakayama Y, Matsuda T, Oda H, Nakamura K and Mabuchi K: Encapsulation of chondrocytes in photopolymerizable styrenated gelatin for cartilage tissue engineering. Tissue Eng 12:2333-2341, 2006.
55. Bazou D, Coakley WT, Hayes AJ and Jackson SK: Long-term viability and proliferation of alginate-encapsulated 3-D HepG2 aggregates formed in an ultrasound trap. Toxicol In Vitro 22:1321-1331, 2008.